As drug substances become increasingly complex, pharmaceutical companies are facing many challenges developing and manufacturing drug substances. More rapid innovation and production is needed to bring solutions to market faster, and keeping expenses in check, or even reducing costs, is top of mind for many pharmaceutical companies.
With high costs of equipment—and the wide-range of equipment needed for sterile liquid dosage, liquid and semi-solid dosage, and solid dosage forms—partnering with a contract development and manufacturing organization (CDMO) or contract manufacturing organization (CMO) can help pharmaceutical companies bring new products or formulas to market without investing in additional infrastructure to support it.
A CMO is a contract manufacturing organization. Just as the name implies, CMOs are contracted by pharmaceutical companies to manufacture drug substances. Manufacturing may include solution, emulsion and nano-suspension, liquid-filled capsules, aseptic filling, terminal sterilization, pre-filled syringe and vials, and tablet and capsules.
Many pharmaceutical companies find themselves tapping into a partner for drug manufacturing because equipment for mass production of some chemicals is very cost prohibitive. It’s more cost effective to outsource than to invest in equipment costs, especially if a product fails in clinical research and further development and production are canceled.
A CDMO is a contract development and manufacturing organization, meaning they not only handle the outsourced manufacturing of drug substances, but also all of the innovation and development work that occurs prior to manufacturing one. This includes development, production and analysis, and pharmaceutical companies no longer need to build and staff dedicated innovation and manufacturing facilities.
Services often offered by CDMO companies include formulation, analytical services, blending, coating, converting, packaging, serialization and shipment. CDMOs can start with a concept or a ready-to-go formula, with preformulation and formulation development services available, as well as clinical trials and commercial production.
When pharmaceutical companies find the right CDMO, they gain flexibility, collaboration and innovation services to help increase speed to market and lower costs by providing expertise and equipment they don’t have in house. As drug substances become more and more complex and rapid innovation and production are needed, CDMOs can accelerate drug development and improve pharmaceutical companies’ bottom lines.
A contract research organization (CRO) is hired by pharmaceutical, biotechnology and medical device manufacturers to handle clinical trials after the drug is developed by the CDMO and is ready for testing. CROs plan, coordinate, execute and supervise all processes involved in developing and running a clinical trial, including selecting a site (when applicable), recruiting participants, monitoring the trial, managing data and more. A CRO manages feedback and requirements from multiple constituents, including manufacturers, trial sponsors, ethical committees, foundations, researchers, legal departments, trial participants and regulatory agencies.
Some CDMOs offer research services themselves or can refer their pharmaceutical company partners to a trusted CRO as needed.
Drug development is complex, and when pharmaceutical companies find the right CDMO, it not only helps them meet deadlines or quickly scale up to meet production demand, but also save cost and time.
• Reduce infrastructure costs by reducing or eliminating the need to invest in additional production and manufacturing space, and eliminate costs associated with purchasing specialized equipment, since the CDMO has access to equipment and facilities.
• Access additional expertise by tapping into researchers with specialized skills—and a wide breadth of experience—to meet the needs of their drug development project and reduce their own payroll costs.
• Meet production deadlines and increased demand with the ability to shift production volume, add a drug variation or scale up without the added expenses of labor, facility space, etc.
Here are a few factors to consider and questions to ask yourself when selecting a CDMO partner for your pharmaceutical company:
A partner is someone (or an organization) who is aligned with your organization and wants to help you achieve your goals. When selecting a CDMO partner, you should look for one who has your best interests in mind, and that comes down to what type of relationship you have with your CDMO partner. Is it rigid with very structured agreements, or flexible to fit the drug development project at hand? Are they able to meet your current needs and help you look (and plan) ahead to future needs?
Another key differentiator of a good partner is their onboarding and collaboration practices. It can be very challenging and cumbersome to transition your drug development to a CDMO who considers you just another client. Find one with top-class communication, opportunities for collaboration and frequent adjustments and access to key project partners to help make the knowledge transfer smoother.
Ascendia Pharmaceuticals specializes in the invention and development of specialty pharmaceutical products and novel formulation technologies, providing pharmaceutical companies with rapid, comprehensive and cost-effective solutions. We’re ready to hit the ground running — contact us today!